First, I Had to Learn How to Pronounce Argatroban
Why the anticoagulant choice was really about flow
This was the first time I saw a patient on argatroban. I had a hard time pronouncing it at first, and I kept breaking it down in my head: R-gat-row-ban. But the pronunciation was not what stayed with me. What caught my attention was the reason it was chosen.
The note said argatroban was selected over bivalirudin due to a high stasis risk. At first, I thought the decision was probably about half-life. Bivalirudin is short-acting. Argatroban is also relatively short-acting. So I assumed the team was comparing how quickly each medication turns on and off. That was part of the picture, but it was not the main issue.
The bigger issue was flow. More specifically, the question was whether the anticoagulant could work reliably in blood that was barely moving.
The patient had HIT, or heparin-induced thrombocytopenia. HIT can be confusing because the platelet count drops, but the real problem is not just “low platelets.” HIT is a clotting problem. Antibodies activate platelets, thrombin generation increases, and the patient becomes more likely to form clots. That is why heparin is stopped, and a non-heparin anticoagulant is needed.
Both argatroban and bivalirudin are direct thrombin inhibitors (DTI). They block thrombin, one of the main enzymes involved in forming a fibrin clot. On the surface, they sound similar. But in a high-stasis situation, the difference matters.
This patient was on VA ECMO and already had an LV thrombus. That tells you blood was not moving well inside the left ventricle. On VA ECMO, especially when the LV is weak or the aortic valve is not opening well, blood can sit in the LV or the aortic root. Blood that sits still wants to clot. That is the stasis problem.
Bivalirudin works well in many ECMO patients, but stagnant blood can create a concern. In areas with good flow, fresh medication keeps circulating through. In a pocket of blood that is barely moving, fresh medication may not reach that space consistently. The blood sample may show a therapeutic aPTT, but that does not prove every low-flow space inside the heart has the same anticoagulant effect.
💡That was the bedside lesson for me. The lab value matters, but the lab value is not the whole patient. That was my light bulb moment. On ECMO, we have to think about where the blood sample is coming from, what the circuit is doing, and what might be happening in parts of the heart where flow is poor.
Argatroban does not carry the same bivalirudin-specific concern in stagnant blood. That does not make it perfect, and it does not make the patient safe from clotting or bleeding. It also does not fix stasis by itself. But in this situation, with HIT and an existing LV thrombus, the team’s choice made more sense. The decision was not only about which medication had the shorter half-life. The decision was about which medication made more sense for a patient who already had evidence of barely moving blood.
Argatroban has its own tradeoff. The liver matters. Argatroban is cleared mainly by the liver, so liver dysfunction, shock liver, hepatic congestion, or a rising bilirubin can cause the medication’s effect to build up. That can increase bleeding risk. So once argatroban is running, the bedside focus has to include more than the infusion rate and the aPTT.
At the bedside, I started thinking about the whole picture. Is the patient bleeding? Are the cannulation sites oozing? Are chest tube outputs changing? Is the oxygenator developing clot? Are the platelets recovering? Is bilirubin climbing? Is the patient pulsatile? Is the aortic valve opening? Is the LV ejecting?
That last part is important because anticoagulation does not fix stagnant blood by itself. If blood is sitting still in the LV, the team still has to address the mechanical problem. Does the patient need more unloading? Is the venting strategy enough? Is the aortic valve opening? Is there enough pulsatility? Is the LV thrombus getting worse?
Those are not just medication questions. Those are ECMO questions.
This case changed how I thought about anticoagulation. At first, argatroban was just a medication I had trouble pronouncing. By the end, it became a reminder that anticoagulation on ECMO is not only about the drug. It is about the patient, the circuit, the flow pattern, and the places where blood is not moving.
The simple bedside lesson is this: this was not just an argatroban-versus-bivalirudin issue. It was a flow issue. In a patient with HIT and high stasis risk on VA ECMO, argatroban may make sense. But the anticoagulant is only one part of the answer.
On VA ECMO, clot risk is not just about what medication is running. It is also about where the blood is moving, and where it is not.
Learn More
For more practical ECMO articles and study tools, visit ecmo143.com and subscribe to this newsletter.
I also built AI ECMO Educator, a free educational tool designed to help clinicians and trainees review ECMO and ECPR concepts, including physiology, cannulation, anticoagulation, circuit management, and troubleshooting. It is built around major ECMO references and literature, but it is not a substitute for institutional protocols, bedside judgment, or consultation with the ECMO team.
Disclaimer: This content is for educational purposes only and does not replace clinical judgment, institutional protocols, or consultation with your ECMO team.
References
Journal of Intensive Care Medicine
Janos Geli, et al. 2021
DOI: 10.1177/0885066621993739Indian Journal of Thoracic and Cardiovascular Surgery
Gaurav Kumar & Ashish Maskey 2021
DOI: 10.1007/s12055-021-01176-3
URL: https://doi.org/10.1007/s12055-021-01176-3guidelinecentral.com
URL: https://www.guidelinecentral.com/drug/46cdf9e6-839c-49c8-9ee1-c30cfdd9368d/argatroban/U.S. National Library of Medicine: DailyMed
May 2026
URL: https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=514ad15b-d060-9d65-e063-6294a90a6188&type=display